US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...

Shares of French late-stage clinical biotech firm Nanobiotix (Euronext: NAN) leapt 17.6% to 3.47 euros after it announced the ...

Privately-held Italian pharma company Italfarmaco and Slovenia-based Medis Therapeutics have announced an exclusive ...

Israeli-headquartered RedHill Biopharma (Nasdaq: RDHL) today revealed its plan to submit a UK marketing authorization ...

European life sciences venture capital firm Sofinnova Partners and French cancer research hospital Gustave Roussy have ...

Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its primary and all key secondary endpoints. The study focused on patients ...

Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, ...

Pharma market insights provider Evaluate today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030.

Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable ...

Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance ...

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...